SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Ewing's sarcoma; Liposarcoma; Osteosarcoma; Rhabdomyosarcoma
- Focus Therapeutic Use
- 26 Feb 2018 Cohort D (Rhabdomyosarcoma) has been added and patient number also increased.
- 19 Feb 2018 Planned number of patients changed from 126 to 150.
- 19 Feb 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.